Dominique Lasne1, Brigitte Jude, Sophie Susen. 1. Laboratoire d'hématologie, Hôpital Necker, 149 Rue de Sèvres, 75743 Paris cedex 15, France. dom.lasne@nck.ap-hop-paris.fr
Abstract
PURPOSE: To review the evolution of knowledge on physiological hemostasis and the main abnormalities that may interfere with hemostasis in the perioperative period. METHODS: Narrative review of the literature, including relevant papers published in English. PRINCIPAL FINDINGS: Physiological hemostasis controls blood fluidity and rapidly induces hemostatic plug formation in order to stop or limit bleeding. The three distinct phases of the hemostatic process, primary hemostasis, coagulation and fibrinolysis are closely linked to each other and precisely regulated in order to efficiently close vessel wounds, promote vascular healing and maintain vessel patency. Primary hemostasis is the result of complex interactions between the vascular wall, platelets and adhesive proteins. Initiation of the coagulation pathway in vivo is secondary to the exposure of tissue factor (TF) and the formation of TF/VIIa complex which can activate both FIX and FX. This initiation phase is followed by a propagation phase with amplification of thrombin generation. Several control mechanisms exist for localizing fibrin formation to the site of injury including tissue factor pathway inhibitor, protein C system, antithrombin, and glycosaminoglycans on the vessel wall. Fibrinolysis is also a highly regulated system that controls fibrin dissolution. Both constitutive and acquired hemostasic defects exist. The consequences of these abnormalities are highly variable according to the type of defect, and to the genetic and environmental background. CONCLUSION: Hemostasis is one of the most complex physiological self-defence systems, not only involved in control of blood fluidity but also interfering in major physiopathological processes. The evolution of our knowledge of the physiology of hemostasis has numerous implications for therapy.
PURPOSE: To review the evolution of knowledge on physiological hemostasis and the main abnormalities that may interfere with hemostasis in the perioperative period. METHODS: Narrative review of the literature, including relevant papers published in English. PRINCIPAL FINDINGS: Physiological hemostasis controls blood fluidity and rapidly induces hemostatic plug formation in order to stop or limit bleeding. The three distinct phases of the hemostatic process, primary hemostasis, coagulation and fibrinolysis are closely linked to each other and precisely regulated in order to efficiently close vessel wounds, promote vascular healing and maintain vessel patency. Primary hemostasis is the result of complex interactions between the vascular wall, platelets and adhesive proteins. Initiation of the coagulation pathway in vivo is secondary to the exposure of tissue factor (TF) and the formation of TF/VIIa complex which can activate both FIX and FX. This initiation phase is followed by a propagation phase with amplification of thrombin generation. Several control mechanisms exist for localizing fibrin formation to the site of injury including tissue factor pathway inhibitor, protein C system, antithrombin, and glycosaminoglycans on the vessel wall. Fibrinolysis is also a highly regulated system that controls fibrin dissolution. Both constitutive and acquired hemostasic defects exist. The consequences of these abnormalities are highly variable according to the type of defect, and to the genetic and environmental background. CONCLUSION: Hemostasis is one of the most complex physiological self-defence systems, not only involved in control of blood fluidity but also interfering in major physiopathological processes. The evolution of our knowledge of the physiology of hemostasis has numerous implications for therapy.
Authors: Sandro B Rizoli; Sandro Scarpelini; Jeannie Callum; Bartolomeu Nascimento; Kenneth G Mann; Ruxandra Pinto; Jan Jansen; Homer C Tien Journal: J Trauma Date: 2011-11
Authors: Julian V Clarke; Julia M Suggs; Deepti Diwan; Jin V Lee; Kim Lipsey; Ananth K Vellimana; Gregory J Zipfel Journal: J Cereb Blood Flow Metab Date: 2020-04-28 Impact factor: 6.200
Authors: Sylwester P Rogula; Hubert M Mutwil; Aleksandra Gąsecka; Marcin Kurzyna; Krzysztof J Filipiak Journal: Cardiol J Date: 2020-11-17 Impact factor: 2.737
Authors: Juan A De Pablo-Moreno; Luis Javier Serrano; Luis Revuelta; María José Sánchez; Antonio Liras Journal: Int J Mol Sci Date: 2022-07-27 Impact factor: 6.208
Authors: Xiaomin Deng; James P Luyendyk; Wei Zou; Jingtao Lu; Ernst Malle; Patricia E Ganey; Robert A Roth Journal: J Pharmacol Exp Ther Date: 2007-05-15 Impact factor: 4.030
Authors: Mariena J A van der Plas; Anders S Andersen; Sheresma Nazir; Nico H van Tilburg; Peter R Oestergaard; Karen A Krogfelt; Jaap T van Dissel; Paul J Hensbergen; Rogier M Bertina; Peter H Nibbering Journal: PLoS One Date: 2014-03-19 Impact factor: 3.240